Key takeaways
Reyvow (lasmiditan) and Ubrelvy (ubrogepant) are both medications used to treat migraine attacks with or without aura in adults. However, they belong to different medication classes. Reyvow is a serotonin agonist, while Ubrelvy is a calcitonin gene-related peptide (CGRP) receptor blocker. Reyvow is taken as a single dose of 50 mg, 100 mg, or 200 mg, and you should not take more than one dose in 24 hours. In contrast, Ubrelvy can be taken in doses of 50 mg or 100 mg, with the option to take a second dose at least 2 hours after the first, up to a maximum of 200 mg per day. Reyvow is a Schedule V controlled substance due to risk of misuse and dependence, whereas Ubrelvy is not a controlled medication. Common side effects of Reyvow include dizziness and sleepiness, while Ubrelvy may cause nausea and dry mouth. Reyvow can interact with medications that increase serotonin levels, raising the risk of serotonin syndrome, while Ubrelvy has many drug interactions, including with certain antibiotics and seizure medications. Neither medication is used to prevent migraines, and both should be taken only as needed for migraine attacks.
